Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Day-to-day measurement of physical activity and risk of atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Driving following defibrillator implantation: a nationwide register-linked survey study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. HIV infection is associated with thoracic and abdominal aortic aneurysms: a prospective matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Nationwide cardiovascular disease admission rates during a second COVID-19 lockdown

    Research output: Contribution to journalLetterResearchpeer-review

  3. Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Day-to-day measurement of physical activity and risk of atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: Reports have suggested an increased risk of aortic and mitral regurgitation associated with oral fluoroquinolones (FQs) resulting in a safety warning published by the European Medicines Agency (EMA). However, these findings have not yet been replicated.

METHODS AND RESULTS: Using Danish administrative registers, we conducted a nested case-control study in a nationwide cohort of individuals between 2005 and 2018. Cases were defined as the first occurrence of aortic or mitral regurgitation. Exposure of interest was the use of oral FQs. Hazard ratios (HRs) with 95% confidence intervals (95% CI) were obtained by fitting time-dependent Cox regression models, with penicillin V as comparator, to assess the association between FQ use and incident valvular regurgitation. We identified 38 370 cases of valvular regurgitation with 1 115 100 matched controls. FQ exposure was not significantly associated with increased rates of aortic or mitral regurgitation (HR 1.02, 95% CI 0.95-1.09) compared with penicillin V users. Investigating the cumulative defined daily doses (cDDD) of FQs yielded similar results with no significant association between increasing FQ use and valvular regurgitation (e.g. HR 1.08, 95% CI 0.95-1.23 for cDDD >10 compared with cDDD 1-5). These results were consistent across several analyses including a cohort of patients with hypertension and using a case definition based on valvular surgical interventions.

CONCLUSIONS: In a nationwide nested case-control study, FQs were not significantly associated with increased rates of valvular regurgitation. Our findings do not support a possible causal connection between FQ exposure and incident valvular regurgitation.

Original languageEnglish
JournalEuropean Heart Journal
Volume42
Issue number30
Pages (from-to)2899-2908
Number of pages10
ISSN0195-668X
DOIs
Publication statusPublished - 7 Aug 2021

    Research areas

  • Case-Control Studies, Cohort Studies, Fluoroquinolones, Heart Valve Diseases, Humans, Mitral Valve Insufficiency/chemically induced

ID: 66609595